Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06473571 · ClinicalTrials.gov registry record · NA

Effects on Dementia Caregivers

A NA study of Dementia, sponsored by University of Central Florida.

Completed
Registry status
NA
Development phase
50
Enrollment target
1
Study location

NCT06473571 is a NA study of Dementia that has completed, run by University of Central Florida. The registered enrollment target is 50 participants, below the 7,723-participant average among 199 other Dementia trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06473571, a NA study of Dementia, has completed, sponsored by University of Central Florida.

COMPLETED
Registry status
NA
Development phase
50 participants
Enrollment target
1
Study location

Study Summary

The Three Good Things (3GT) is a gratitude list intervention that is empirically supported (Emmons \& McCullough, 2003; Seligman et al., 2005) and is a low-cost, easily accessible tool for medical and mental providers to recommend and dementia caregivers to implement independently. Thus, this study aims to investigate the feasibility of use of 3GT in the dementia caregiving population and investigate potential therapeutic mechanisms of the intervention.

Conditions Studied

Interventions

  • OTHER Control Group
  • OTHER Intervention Protocol (The 3GT)

Study Locations (1)

Florida

  • University of Central Florida - Orlando

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2023-03-14
Est. Completion 2024-01-04
Phase NA

Sponsor

University of Central Florida

91 total trials

What the Registry Record Tells You About NCT06473571

The ClinicalTrials.gov registry entry for NCT06473571 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 7,723-participant average among 199 other Dementia trials with a reported enrollment target (99% lower). The listed sponsor is University of Central Florida, which has 91 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Dementia appearing as the primary indexed condition, and to 2 interventions - of which Control Group is the first listed.

NCT06473571 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT06473571 about?

NCT06473571 is a clinical study titled "Effects on Dementia Caregivers". The Three Good Things (3GT) is a gratitude list intervention that is empirically supported (Emmons \& McCullough, 2003; Seligman et al., 2005) and is a low-cost, easily accessible tool for medical and mental providers to recommend and dementia caregivers to implement independently. Thus, this study ...

What is the current status of trial NCT06473571?

This trial is currently completed. It is a NA study. The enrollment target is 50 participants. The study started on 2023-03-14. Estimated completion is 2024-01-04.

What conditions does trial NCT06473571 study?

This clinical trial studies the following conditions: Dementia.

What interventions are being tested in trial NCT06473571?

The interventions under investigation include: Control Group (OTHER), Intervention Protocol (The 3GT) (OTHER).

Who is sponsoring clinical trial NCT06473571?

This trial is sponsored by University of Central Florida, which has 91 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06473571 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Dementia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.